{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T21:11:46Z","timestamp":1792444306348,"version":"4.5.0"},"reference-count":226,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,17]],"date-time":"2022-07-17T00:00:00Z","timestamp":1658016000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008981","name":"Department of Anesthesiology, Medical College of Wisconsin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008981","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-21-1-0048"],"award-info":[{"award-number":["W81XWH-21-1-0048"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.apsb.2022.07.010","type":"journal-article","created":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T18:30:48Z","timestamp":1658255448000},"page":"1400-1428","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Progress in non-viral localized delivery of siRNA therapeutics for pulmonary diseases"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8608-6949","authenticated-orcid":false,"given":"Jingjing","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziting","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilrasbonu","family":"Vohidova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9782-2323","authenticated-orcid":false,"given":"James N.","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8138-7611","authenticated-orcid":false,"given":"Nitin","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2022.07.010_bib1","author":"World"},{"key":"10.1016\/j.apsb.2022.07.010_bib2","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.7150\/thno.15246","article-title":"Pharmacokinetic behaviors of intravenously administered siRNA in glandular tissues","volume":"6","author":"Huang","year":"2016","journal-title":"Theranostics"},{"key":"10.1016\/j.apsb.2022.07.010_bib3","article-title":"Is viral vector gene delivery more effective using biomaterials?.","volume":"10","author":"Wang","year":"2021","journal-title":"Adv Healthc Mater"},{"key":"10.1016\/j.apsb.2022.07.010_bib4","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1089\/nat.2017.0715","article-title":"Journey of siRNA: clinical developments and targeted delivery","volume":"28","author":"Nikam","year":"2018","journal-title":"Nucleic Acid Therapeut"},{"key":"10.1016\/j.apsb.2022.07.010_bib5","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3389\/fonc.2019.00297","article-title":"Gene therapy leaves a vicious cycle","volume":"9","author":"Goswami","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.apsb.2022.07.010_bib6","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.ymthe.2020.01.001","article-title":"Immune responses to viral gene therapy vectors","volume":"28","author":"Shirley","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2022.07.010_bib7","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nrd2742","article-title":"Knocking down barriers: advances in siRNA delivery","volume":"8","author":"Whitehead","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2022.07.010_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2016.11.036","article-title":"Does size really matter?: relationship of particle size to lung deposition and exhaled fraction","volume":"139","author":"Jabbal","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.apsb.2022.07.010_bib9","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/bjp.2008.349","article-title":"Viral vectors: from virology to transgene expression","volume":"157","author":"Bouard","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.apsb.2022.07.010_bib10","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1146\/annurev-bioeng-071813-104938","article-title":"Viral vectors for gene therapy: translational and clinical outlook","volume":"17","author":"Kotterman","year":"2015","journal-title":"Annu Rev Biomed Eng"},{"key":"10.1016\/j.apsb.2022.07.010_bib11","series-title":"Non-viral delivery systems in gene therapy","author":"Gasc\u00f3n","year":"2013"},{"key":"10.1016\/j.apsb.2022.07.010_bib12","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1208\/s12248-021-00608-7","article-title":"Non-viral vectors in gene therapy: recent development, challenges, and prospects","volume":"23","author":"Zu","year":"2021","journal-title":"AAPS J"},{"key":"10.1016\/j.apsb.2022.07.010_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.addr.2011.02.006","article-title":"Pulmonary delivery of therapeutic siRNA","volume":"64","author":"Lam","year":"2012","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2022.07.010_bib14","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","article-title":"The current state and future directions of RNAi-based therapeutics","volume":"18","author":"Setten","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2022.07.010_bib15","doi-asserted-by":"crossref","first-page":"8800","DOI":"10.1073\/pnas.0912186107","article-title":"A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus","volume":"107","author":"DeVincenzo","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2022.07.010_bib16","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1164\/rccm.201003-0422OC","article-title":"RNA interference therapy in lung transplant patients infected with respiratory syncytial virus","volume":"183","author":"Zamora","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.apsb.2022.07.010_bib17","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1002\/biot.201100054","article-title":"Current progress of siRNA\/shRNA therapeutics in clinical trials","volume":"6","author":"Burnett","year":"2011","journal-title":"Biotechnol J"},{"key":"10.1016\/j.apsb.2022.07.010_bib18","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jconrel.2020.07.011","article-title":"Pharmacokinetics of inhaled nanotherapeutics for pulmonary delivery","volume":"326","author":"Shen","year":"2020","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2022.07.010_bib19","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1046\/j.1365-2125.2003.01893.x","article-title":"Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications","volume":"56","author":"Labiris","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.apsb.2022.07.010_bib20","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ijpharm.2011.12.006","article-title":"Evaluation of metered dose inhaler spray velocities using phase Doppler anemometry (PDA)","volume":"423","author":"Liu","year":"2012","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2022.07.010_bib21","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1089\/jam.1996.9.215","article-title":"Effect of inhalation flow rate on the dosing characteristics of dry powder inhaler (DPI) and metered dose inhaler (MDI) products","volume":"9","author":"Ross","year":"1996","journal-title":"J Aerosol Med"},{"key":"10.1016\/j.apsb.2022.07.010_bib22","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1021\/mp4006358","article-title":"Poly(amidoamine) dendrimer nanocarriers and their aerosol formulations for siRNA delivery to the lung epithelium","volume":"11","author":"Conti","year":"2014","journal-title":"Mol Pharm"},{"key":"10.1016\/j.apsb.2022.07.010_bib23","doi-asserted-by":"crossref","first-page":"E54","DOI":"10.1208\/pt040454","article-title":"Aerodynamic particle size analysis of aerosols from pressurized metered-dose inhalers: comparison of Andersen 8-stage cascade impactor, next generation pharmaceutical impactor, and model 3321 Aerodynamic Particle Sizer aerosol spectrometer","volume":"4","author":"Mitchell","year":"2003","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.apsb.2022.07.010_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2006.02.014","article-title":"Prospects of formulating proteins\/peptides as aerosols for pulmonary drug delivery","volume":"314","author":"Shoyele","year":"2006","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2022.07.010_bib25","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jconrel.2009.10.010","article-title":"Spray drying of siRNA-containing PLGA nanoparticles intended for inhalation","volume":"142","author":"Jensen","year":"2010","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2022.07.010_bib26","article-title":"Impact of crystalline and amorphous matrices on successful spray drying of siRNA polyplexes for inhalation of nano-in-microparticles","volume":"4","author":"Keil","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.apsb.2022.07.010_bib27","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.apsb.2021.08.009","article-title":"Pulmonary delivery of siRNA against acute lung injury\/acute respiratory distress syndrome","volume":"12","author":"Zoulikha","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2022.07.010_bib28","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/rr58","article-title":"The lung as a route for systemic delivery of therapeutic proteins and peptides","volume":"2","author":"Agu","year":"2001","journal-title":"Respir Res"},{"key":"10.1016\/j.apsb.2022.07.010_bib29","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ijpharm.2017.11.049","article-title":"Insights on animal models to investigate inhalation therapy: relevance for biotherapeutics","volume":"536","author":"Guillon","year":"2018","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2022.07.010_bib30","article-title":"Gene silencing of SOCS3 by siRNA intranasal delivery inhibits asthma phenotype in mice","volume":"9","author":"Zafra","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2022.07.010_bib31","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.omtn.2018.07.009","article-title":"Intratracheal administration of siRNA dry powder targeting vascular endothelial growth factor inhibits lung tumor growth in mice","volume":"12","author":"Miwata","year":"2018","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.apsb.2022.07.010_bib32","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0169-409X(98)00073-8","article-title":"Intranasal insulin delivery and therapy","volume":"35","author":"Hinchcliffe","year":"1999","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2022.07.010_bib33","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3390\/ph6020223","article-title":"RNAi therapeutic platforms for lung diseases","volume":"6","author":"Fujita","year":"2013","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.apsb.2022.07.010_bib34","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.3390\/molecules21091249","article-title":"Delivery of RNAi therapeutics to the airways-from bench to bedside","volume":"21","author":"Qiu","year":"2016","journal-title":"Molecules"},{"key":"10.1016\/j.apsb.2022.07.010_bib35","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jconrel.2016.05.054","article-title":"Pulmonary administration of small interfering RNA: the route to go?.","volume":"235","author":"Ruigrok","year":"2016","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2022.07.010_bib36","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1021\/ar200110p","article-title":"Nonviral pulmonary delivery of siRNA","volume":"45","author":"Merkel","year":"2012","journal-title":"Acc Chem Res"},{"key":"10.1016\/j.apsb.2022.07.010_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2010.12.040","article-title":"Influence of particle size on regional lung deposition\u2014what evidence is there?.","volume":"406","author":"Carvalho","year":"2011","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2022.07.010_bib38","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4103\/2230-973X.108959","article-title":"Exploring targeted pulmonary delivery for treatment of lung cancer","volume":"3","author":"Goel","year":"2013","journal-title":"Int J Pharm Investig"},{"issue":"Suppl 2","key":"10.1016\/j.apsb.2022.07.010_bib39","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1089\/jamp.2010.0836","article-title":"The particle has landed\u2014characterizing the fate of inhaled pharmaceuticals","volume":"23","author":"Patton","year":"2010","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"10.1016\/j.apsb.2022.07.010_bib40","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S1773-2247(10)50026-1","article-title":"Polymeric nanocarriers for drug delivery to the lung","volume":"20","author":"Lebhardt","year":"2010","journal-title":"J Drug Deliv Sci Technol"},{"key":"10.1016\/j.apsb.2022.07.010_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120940","article-title":"Antibody-siRNA conjugates (ARCs) using multifunctional peptide as a tumor enzyme cleavable linker mediated effective intracellular delivery of siRNA","volume":"606","author":"Yu","year":"2021","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2022.07.010_bib42","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1126\/science.276.5320.1868","article-title":"Large porous particles for pulmonary drug delivery","volume":"276","author":"Edwards","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.apsb.2022.07.010_bib43","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.2147\/IJN.S169399","article-title":"Overcoming multidrug resistance through inhalable siRNA nanoparticles-decorated porous microparticles based on supercritical fluid technology","volume":"13","author":"Xu","year":"2018","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.apsb.2022.07.010_bib44","doi-asserted-by":"crossref","first-page":"9726","DOI":"10.1002\/anie.200803526","article-title":"Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that \u201cslip\u201d through the human mucus barrier","volume":"47","author":"Wang","year":"2008","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.apsb.2022.07.010_bib45","doi-asserted-by":"crossref","first-page":"9217","DOI":"10.1021\/acsnano.5b03876","article-title":"Impact of surface polyethylene glycol (PEG) density on biodegradable nanoparticle transport in mucus ex\u00a0vivo and distribution in\u00a0vivo","volume":"9","author":"Xu","year":"2015","journal-title":"ACS Nano"},{"key":"10.1016\/j.apsb.2022.07.010_bib46","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jconrel.2013.04.018","article-title":"Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA","volume":"171","author":"Taratula","year":"2013","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2022.07.010_bib47","article-title":"Pro-peptide-reinforced, mucus-penetrating pulmonary siRNA delivery mitigates cytokine storm in pneumonia","volume":"31","author":"Yang","year":"2021","journal-title":"Adv Funct Mater"},{"key":"10.1016\/j.apsb.2022.07.010_bib48","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1021\/acs.nanolett.9b04957","article-title":"Fluorinated \u03b1-helical polypeptides synchronize mucus permeation and cell penetration toward highly efficient pulmonary siRNA delivery against acute lung injury","volume":"20","author":"Ge","year":"2020","journal-title":"Nano Lett"},{"key":"10.1016\/j.apsb.2022.07.010_bib49","first-page":"1613","article-title":"Pulmonary surfactant: an interdisciplinary approach","volume":"57","author":"Notter","year":"1984","journal-title":"J Appl Physiol Respir Exerc Physiol"},{"key":"10.1016\/j.apsb.2022.07.010_bib50","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1089\/hum.1997.8.4-431","article-title":"Pulmonary surfactant inhibits cationic liposome-mediated gene delivery to respiratory epithelial cells in\u00a0vitro","volume":"8","author":"Duncan","year":"1997","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.apsb.2022.07.010_bib51","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jconrel.2015.09.004","article-title":"Bio-inspired materials in drug delivery: exploring the role of pulmonary surfactant in siRNA inhalation therapy","volume":"220","author":"De Backer","year":"2015","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2022.07.010_bib52","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/nnano.2012.207","article-title":"Biomolecular coronas provide the biological identity of nanosized materials","volume":"7","author":"Monopoli","year":"2012","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.apsb.2022.07.010_bib53","doi-asserted-by":"crossref","first-page":"952","DOI":"10.3109\/17435390.2014.992487","article-title":"Surfactant protein A (SP-A) inhibits agglomeration and macrophage uptake of toxic amine modified nanoparticles","volume":"9","author":"McKenzie","year":"2015","journal-title":"Nanotoxicology"},{"key":"10.1016\/j.apsb.2022.07.010_bib54","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jconrel.2015.08.030","article-title":"Hybrid pulmonary surfactant-coated nanogels mediate efficient in\u00a0vivo delivery of siRNA to murine alveolar macrophages","volume":"217","author":"De Backer","year":"2015","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2022.07.010_bib55","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202001650","article-title":"siRNA therapeutics against respiratory viral infections-what have we learned for potential COVID-19 therapies?.","volume":"10","author":"Mehta","year":"2021","journal-title":"Adv Healthc Mater"},{"key":"10.1016\/j.apsb.2022.07.010_bib56","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/s41579-019-0149-x","article-title":"Respiratory syncytial virus entry and how to block it","volume":"17","author":"Battles","year":"2019","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.apsb.2022.07.010_bib57","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1471-2180-1-34","article-title":"Phenotypic silencing of cytoplasmic genes using sequence-specific double-stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA viruses","volume":"1","author":"Bitko","year":"2001","journal-title":"BMC Microbiol"},{"key":"10.1016\/j.apsb.2022.07.010_bib58","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nm1164","article-title":"Inhibition of respiratory viruses by nasally administered siRNA","volume":"11","author":"Bitko","year":"2005","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2022.07.010_bib59","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.antiviral.2007.11.009","article-title":"Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV)","volume":"77","author":"DeVincenzo","year":"2008","journal-title":"Antiviral Res"},{"key":"10.1016\/j.apsb.2022.07.010_bib60","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.healun.2015.08.012","article-title":"ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus infection in lung transplant recipients","volume":"35","author":"Gottlieb","year":"2016","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.apsb.2022.07.010_bib61","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jviromet.2016.07.012","article-title":"Design and validation of small interfering RNA on respiratory syncytial virus M2-2 gene: a potential approach in RNA interference on viral replication","volume":"236","author":"Chin","year":"2016","journal-title":"J Virol Methods"},{"key":"10.1016\/j.apsb.2022.07.010_bib62","doi-asserted-by":"crossref","first-page":"11259","DOI":"10.1073\/pnas.96.20.11259","article-title":"The M2-2 protein of human respiratory syncytial virus is a regulatory factor involved in the balance between RNA replication and transcription","volume":"96","author":"Bermingham","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2022.07.010_bib63","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1089\/hum.2013.142","article-title":"Small interfering RNAs targeted to interleukin-4 and respiratory syncytial virus reduce airway inflammation in a mouse model of virus-induced asthma exacerbation","volume":"25","author":"Khaitov","year":"2014","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.apsb.2022.07.010_bib64","unstructured":"Ritchie H, Mathieu E, Rod\u00e9s-Guirao L, Appel C, Giattino C, Ortiz-Ospina E, et\u00a0al. Coronavirus Pandemic (COVID-19). Available from: https:\/\/ourworldindata.org\/coronavirus."},{"key":"10.1016\/j.apsb.2022.07.010_bib65","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3390\/v12020244","article-title":"Systematic comparison of two animal-to-human transmitted human coronaviruses: SARS-CoV-2 and SARS-CoV","volume":"12","author":"Xu","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.apsb.2022.07.010_bib66","doi-asserted-by":"crossref","first-page":"7523","DOI":"10.1128\/JVI.78.14.7523-7527.2004","article-title":"Inhibition of severe acute respiratory syndrome virus replication by small interfering RNAs in mammalian cells","volume":"78","author":"Wang","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.apsb.2022.07.010_bib67","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1038\/nm1280","article-title":"Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque","volume":"11","author":"Li","year":"2005","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2022.07.010_bib68","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1111\/all.14850","article-title":"Silencing of SARS-CoV-2 with modified siRNA-peptide dendrimer formulation","volume":"76","author":"Khaitov","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.apsb.2022.07.010_bib69","doi-asserted-by":"crossref","unstructured":"Ambike S, Cheng CC, Afridi S, Feuerherd M, Hagen P, Grass V, et\u00a0al. Systematic analysis of RNAi-accessible SARS-CoV-2 replication steps identifies ORF1 as promising target. Available from: https:\/\/doi.org\/10.21203\/rs.3.rs-105129\/v1.","DOI":"10.21203\/rs.3.rs-105129\/v1"},{"key":"10.1016\/j.apsb.2022.07.010_bib70","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41598-017-00200-0","article-title":"Hybrid inorganic-organic capsules for efficient intracellular delivery of novel siRNAs against influenza A (H1N1) virus infection","volume":"7","author":"Timin","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2022.07.010_bib71","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1021\/mp500745v","article-title":"Inhalable dry powder formulations of siRNA and pH-responsive peptides with antiviral activity against H1N1 Influenza virus","volume":"12","author":"Liang","year":"2015","journal-title":"Mol Pharm"},{"key":"10.1016\/j.apsb.2022.07.010_bib72","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s13346-017-0426-z","article-title":"Inhibiting influenza virus replication and inducing protection against lethal influenza virus challenge through chitosan nanoparticles loaded by siRNA","volume":"8","author":"Jamali","year":"2018","journal-title":"Drug Deliv Transl Res"},{"key":"10.1016\/j.apsb.2022.07.010_bib73","doi-asserted-by":"crossref","first-page":"259","DOI":"10.18821\/0507-4088-2017-62-6-259-265","article-title":"Comparison of influenza A virus inhibition in\u00a0vitro by siRNA complexes with chitosan derivatives, polyethylenimine and hybrid polyarginine-inorganic microparticles","volume":"62","author":"Petrova-Brodskaya","year":"2017","journal-title":"Problems of Virology Russian Journal"},{"key":"10.1016\/j.apsb.2022.07.010_bib74","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.antiviral.2018.08.003","article-title":"Inhibition of influenza A virus by mixed siRNAs, targeting the PA, NP, and NS genes, delivered by hybrid microcarriers","volume":"158","author":"Brodskaia","year":"2018","journal-title":"Antiviral Res"},{"key":"10.1016\/j.apsb.2022.07.010_bib75","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.bbrc.2007.10.196","article-title":"Inhibition of highly pathogenic avian H5N1 influenza virus replication by RNA oligonucleotides targeting NS1 gene","volume":"365","author":"Wu","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.apsb.2022.07.010_bib76","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.bbagen.2007.12.010","article-title":"Inhibition of bfl-1\/A1 by siRNA inhibits mycobacterial growth in THP-1 cells by enhancing phagosomal acidification","volume":"1780","author":"Dhiman","year":"2008","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.apsb.2022.07.010_bib77","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1083\/jcb.200603026","article-title":"Higher order Rab programming in phagolysosome biogenesis","volume":"174","author":"Roberts","year":"2006","journal-title":"J Cell Biol"},{"key":"10.1016\/j.apsb.2022.07.010_bib78","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.tube.2010.11.004","article-title":"Local pulmonary immunotherapy with siRNA targeting TGF\u03b21 enhances antimicrobial capacity in Mycobacterium tuberculosis infected mice","volume":"91","author":"Rosas-Taraco","year":"2011","journal-title":"Tuberculosis"},{"key":"10.1016\/j.apsb.2022.07.010_bib79","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1165\/rcmb.2008-0363OC","article-title":"Intrapulmonary delivery of XCL1-targeting small interfering RNA in mice chronically infected with Mycobacterium tuberculosis","volume":"41","author":"Rosas-Taraco","year":"2009","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.apsb.2022.07.010_bib80","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41591-018-0340-z","article-title":"Current and future influenza vaccines","volume":"25","author":"Yamayoshi","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2022.07.010_bib81","doi-asserted-by":"crossref","first-page":"505","DOI":"10.18388\/abp.2014_1871","article-title":"Influenza viruses resistant to neuraminidase inhibitors","volume":"61","author":"Nitsch-Osuch","year":"2014","journal-title":"Acta Biochim Pol"},{"key":"10.1016\/j.apsb.2022.07.010_bib82","article-title":"Adamantane-resistant influenza A viruses in the world (1902\u20132013): frequency and distribution of M2 gene mutations","volume":"10","author":"Dong","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2022.07.010_bib83","doi-asserted-by":"crossref","DOI":"10.1038\/srep15279","article-title":"H3N2 mismatch of 2014\u201315 northern hemisphere influenza vaccines and head-to-head comparison between human and ferret antisera derived antigenic maps","volume":"5","author":"Xie","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2022.07.010_bib84","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1073\/pnas.0437841100","article-title":"RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription","volume":"100","author":"Ge","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2022.07.010_bib85","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0005671","article-title":"Small interfering RNA targeting M2 gene induces effective and long term inhibition of influenza A virus replication","volume":"4","author":"Sui","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2022.07.010_bib86","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.addr.2016.04.013","article-title":"Potential and development of inhaled RNAi therapeutics for the treatment of pulmonary tuberculosis","volume":"102","author":"Man","year":"2016","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2022.07.010_bib87","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.biocel.2010.12.014","article-title":"Bfl-1\/A1 acts as a negative regulator of autophagy in mycobacteria infected macrophages","volume":"43","author":"Kathania","year":"2011","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.apsb.2022.07.010_bib88","article-title":"The tuberculous granuloma: an unsuccessful host defence mechanism providing a safety shelter for the bacteria?.","volume":"2012","author":"Miranda","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.apsb.2022.07.010_bib89","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1128\/IAI.72.5.2628-2634.2004","article-title":"Down-modulation of lung immune responses by interleukin-10 and transforming growth factor beta (TGF-beta) and analysis of TGF-beta receptors I and II in active tuberculosis","volume":"72","author":"Bonecini-Almeida","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.apsb.2022.07.010_bib90","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/s41392-020-00345-x","article-title":"Progress in the mechanism and targeted drug therapy for COPD","volume":"5","author":"Wang","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.apsb.2022.07.010_bib91","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.tips.2020.04.007","article-title":"Therapeutic RNA strategies for chronic obstructive pulmonary disease","volume":"41","author":"Mei","year":"2020","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.apsb.2022.07.010_bib92","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/164_2016_64","article-title":"\u03b22","volume":"237","author":"Billington","year":"2017","journal-title":"Agonists. Handb Exp Pharmacol"},{"issue":"4","key":"10.1016\/j.apsb.2022.07.010_bib93","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/01.mcg.0000155140.63510.cd","article-title":"Cystic fibrosis: an overview","volume":"39","author":"Turcios","year":"2005","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.apsb.2022.07.010_bib94","doi-asserted-by":"crossref","first-page":"a009555","DOI":"10.1101\/cshperspect.a009555","article-title":"Status of fluid and electrolyte absorption in cystic fibrosis","volume":"3","author":"Reddy","year":"2013","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.apsb.2022.07.010_bib95","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1038\/s41598-017-00662-2","article-title":"Delivery of ENaC siRNA to epithelial cells mediated by a targeted nanocomplex: a therapeutic strategy for cystic fibrosis","volume":"7","author":"Manunta","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2022.07.010_bib96","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1089\/jamp.2017.1364","article-title":"Hybrid lipid\/polymer nanoparticles for pulmonary delivery of siRNA: development and fate upon in\u00a0vitro deposition on the human epithelial airway barrier","volume":"31","author":"d'Angelo","year":"2018","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"10.1016\/j.apsb.2022.07.010_bib97","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1039\/C9NR06382J","article-title":"Targeted delivery of Chil3\/Chil4 siRNA to alveolar macrophages using ternary complexes composed of HMG and oligoarginine micelles","volume":"12","author":"Choi","year":"2020","journal-title":"Nanoscale"},{"key":"10.1016\/j.apsb.2022.07.010_bib98","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.ijpharm.2015.06.017","article-title":"Cationic polyaspartamide-based nanocomplexes mediate siRNA entry and down-regulation of the pro-inflammatory mediator high mobility group box 1 in airway epithelial cells","volume":"491","author":"Di Gioia","year":"2015","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2022.07.010_bib99","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/gt.2008.15","article-title":"Small interfering RNA against interleukin-5 decreases airway eosinophilia and hyper-responsiveness","volume":"15","author":"Huang","year":"2008","journal-title":"Gene Ther"},{"key":"10.1016\/j.apsb.2022.07.010_bib100","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.4049\/jimmunol.1202416","article-title":"Receptor-interacting protein 2 gene silencing attenuates allergic airway inflammation","volume":"191","author":"Goh","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.apsb.2022.07.010_bib101","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1165\/rcmb.2009-0051OC","article-title":"T cell treatment with small interfering RNA for suppressor of cytokine signaling 3 modulates allergic airway responses in a murine model of asthma","volume":"44","author":"Moriwaki","year":"2011","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.apsb.2022.07.010_bib102","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/mi.2009.130","article-title":"Intranasally delivered siRNA targeting PI3K\/Akt\/mTOR inflammatory pathways protects from aspergillosis","volume":"3","author":"Bonifazi","year":"2010","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.apsb.2022.07.010_bib103","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.4238\/2012.September.12.6","article-title":"Bottom-up assembly of RNA nanoparticles containing phi29 motor pRNA to silence the asthma STAT5b gene","volume":"11","author":"Qiu","year":"2012","journal-title":"Genet Mol Res"},{"key":"10.1016\/j.apsb.2022.07.010_bib104","doi-asserted-by":"crossref","first-page":"7501","DOI":"10.4049\/jimmunol.0713433","article-title":"Small interfering RNA against transcription factor STAT6 inhibits allergic airway inflammation and hyperreactivity in mice","volume":"182","author":"Darcan-Nicolaisen","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.apsb.2022.07.010_bib105","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.molimm.2012.06.011","article-title":"Effect of locally administered Syk siRNA on allergen-induced arthritis and asthma","volume":"53","author":"Huang","year":"2013","journal-title":"Mol Immunol"},{"key":"10.1016\/j.apsb.2022.07.010_bib106","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/gt.2017.83","article-title":"A new combination therapy for asthma using dual-function dexamethasone-conjugated polyethylenimine and vitamin D binding protein siRNA","volume":"24","author":"Choi","year":"2017","journal-title":"Gene Ther"},{"key":"10.1016\/j.apsb.2022.07.010_bib107","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1016\/j.nano.2017.08.001","article-title":"Local delivery of siRNA-loaded calcium phosphate nanoparticles abates pulmonary inflammation","volume":"13","author":"Frede","year":"2017","journal-title":"Nanomedicine"},{"key":"10.1016\/j.apsb.2022.07.010_bib108","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0002-9440(10)61240-0","article-title":"Silencing of Fas, but not caspase-8, in lung epithelial cells ameliorates pulmonary apoptosis, inflammation, and neutrophil influx after hemorrhagic shock and sepsis","volume":"167","author":"Perl","year":"2005","journal-title":"Am J Pathol"},{"key":"10.1016\/j.apsb.2022.07.010_bib109","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1189\/jlb.1004617","article-title":"In\u00a0vivo gene silencing (with siRNA) of pulmonary expression of MIP-2 versus KC results in divergent effects on hemorrhage-induced, neutrophil-mediated septic acute lung injury","volume":"77","author":"Lomas-Neira","year":"2005","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.apsb.2022.07.010_bib110","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.mvr.2005.08.003","article-title":"Pre-B-cell-colony-enhancing factor is critically involved in thrombin-induced lung endothelial cell barrier dysregulation","volume":"70","author":"Ye","year":"2005","journal-title":"Microvasc Res"},{"key":"10.1016\/j.apsb.2022.07.010_bib111","doi-asserted-by":"crossref","first-page":"L1094","DOI":"10.1152\/ajplung.2001.280.6.L1094","article-title":"IL-8 activates endothelial cell CXCR1 and CXCR2 through Rho and Rac signaling pathways","volume":"280","author":"Schraufstatter","year":"2001","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.apsb.2022.07.010_bib112","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2020.601155","article-title":"Optimizing the intracellular delivery of therapeutic anti-inflammatory TNF-\u03b1 siRNA to activated macrophages using lipidoid-polymer hybrid nanoparticles","volume":"8","author":"Lokras","year":"2021","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1016\/j.apsb.2022.07.010_bib113","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ejpb.2020.11.024","article-title":"siRNA delivery to macrophages using aspherical, nanostructured microparticles as delivery system for pulmonary administration","volume":"158","author":"Fischer","year":"2021","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.apsb.2022.07.010_bib114","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s10753-016-0494-0","article-title":"Exosomes from iPSCs delivering siRNA attenuate intracellular adhesion molecule-1 expression and neutrophils adhesion in pulmonary microvascular endothelial cells","volume":"40","author":"Ju","year":"2017","journal-title":"Inflammation"},{"key":"10.1016\/j.apsb.2022.07.010_bib115","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/j.ymthe.2018.06.007","article-title":"Exosome-mediated small RNA delivery: a novel therapeutic approach for inflammatory lung responses","volume":"26","author":"Zhang","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2022.07.010_bib116","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jconrel.2019.10.030","article-title":"Treatment of acute lung injury and early- and late-stage pulmonary fibrosis with combination emulsion siRNA polyplexes","volume":"314","author":"Wang","year":"2019","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2022.07.010_bib117","doi-asserted-by":"crossref","first-page":"L801","DOI":"10.1152\/ajplung.00108.2019","article-title":"Blockade of endothelial, but not epithelial, cell expression of PD-L1 following\u00a0severe shock attenuates the development of indirect acute lung injury in mice","volume":"318","author":"Xu","year":"2020","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.apsb.2022.07.010_bib118","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.phrs.2018.10.016","article-title":"Gene silencing of receptor-interacting protein 2 protects against cigarette smoke-induced acute lung injury","volume":"139","author":"Dong","year":"2019","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.apsb.2022.07.010_bib119","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jconrel.2013.12.008","article-title":"Combined delivery of HMGB-1 box A peptide and S1PLyase siRNA in animal models of acute lung injury","volume":"175","author":"Oh","year":"2014","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2022.07.010_bib120","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1021\/acs.biomac.7b00572","article-title":"Anti-inflammatory effect of anti-TNF-\u03b1 SiRNA cationic phosphorus dendrimer nanocomplexes administered intranasally in a murine acute lung injury model","volume":"18","author":"Bohr","year":"2017","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.apsb.2022.07.010_bib121","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejpb.2020.08.009","article-title":"Treatment of acute lung inflammation by pulmonary delivery of anti-TNF-\u03b1 siRNA with PAMAM dendrimers in a murine model","volume":"156","author":"Bohr","year":"2020","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.apsb.2022.07.010_bib122","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3389\/fbioe.2019.00406","article-title":"Nanomedicine approaches for the pulmonary\u00a0treatment of cystic fibrosis","volume":"7","author":"Velino","year":"2019","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1016\/j.apsb.2022.07.010_bib123","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.prrv.2007.02.009","article-title":"Mucolytics in cystic fibrosis","volume":"8","author":"Henke","year":"2007","journal-title":"Paediatr Respir Rev"},{"key":"10.1016\/j.apsb.2022.07.010_bib124","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1164\/rccm.200705-664OC","article-title":"Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health","volume":"176","author":"Flume","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.apsb.2022.07.010_bib125","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1807119","article-title":"VX-659\u2013Tezacaftor\u2013Ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles","volume":"379","author":"Davies","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2022.07.010_bib128","series-title":"Translate Bio, Inc. A Phase 1\/2","year":"2020"},{"key":"10.1016\/j.apsb.2022.07.010_bib129","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1080\/14728222.2018.1501361","article-title":"The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis lung disease","volume":"22","author":"Moore","year":"2018","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.apsb.2022.07.010_bib130","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1136\/thoraxjnl-2017-210670","article-title":"Effective silencing of ENaC by siRNA delivered with epithelial-targeted nanocomplexes in human cystic fibrosis cells and in mouse lung","volume":"73","author":"Tagalakis","year":"2018","journal-title":"Thorax"},{"key":"10.1016\/j.apsb.2022.07.010_bib132","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/ACI.0b013e32834ecb4f","article-title":"The potential use of tyrosine kinase inhibitors in severe asthma","volume":"12","author":"Guntur","year":"2012","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.apsb.2022.07.010_bib133","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jaci.2004.03.044","article-title":"Essential role of dendritic cell CD80\/CD86 costimulation in the induction, but not reactivation, of TH2 effector responses in a mouse model of asthma","volume":"114","author":"van Rijt","year":"2004","journal-title":"J Allergy Clin Immunol"},{"issue":"9537","key":"10.1016\/j.apsb.2022.07.010_bib134","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S0140-6736(06)69290-8","article-title":"Asthma: defining of the persistent adult phenotypes","volume":"368","author":"Wenzel","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2022.07.010_bib135","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1067\/mai.2001.117929","article-title":"IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines","volume":"108","author":"Molet","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.apsb.2022.07.010_bib136","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1164\/rccm.200801-086OC","article-title":"IL-23 and Th17 cells enhance Th2-cell-mediated eosinophilic airway inflammation in mice","volume":"178","author":"Wakashin","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.apsb.2022.07.010_bib137","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/nri2870","article-title":"Functions of T cells in asthma: more than just TH2 cells","volume":"10","author":"Lloyd","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.apsb.2022.07.010_bib138","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1182\/blood.V79.12.3101.bloodjournal79123101","article-title":"Interleukin-5, eosinophils, and disease","volume":"79","author":"Sanderson","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2022.07.010_bib139","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1056\/NEJM199010113231505","article-title":"Eosinophilic inflammation in asthma","volume":"323","author":"Bousquet","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2022.07.010_bib140","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1165\/rcmb.2012-0080TR","article-title":"Targeting interleukin-4 in asthma:\u00a0lost in translation?.","volume":"47","author":"Maes","year":"2012","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.apsb.2022.07.010_bib141","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.apsb.2022.07.010_bib142","doi-asserted-by":"crossref","first-page":"14395","DOI":"10.1073\/pnas.95.24.14395","article-title":"Liver degeneration and lymphoid deficiencies in mice lacking suppressor of cytokine signaling-1","volume":"95","author":"Starr","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2022.07.010_bib143","doi-asserted-by":"crossref","first-page":"L908","DOI":"10.1152\/ajplung.00115.2011","article-title":"Intra-airway administration of small interfering RNA targeting\u00a0plasminogen activator inhibitor-1 attenuates allergic asthma\u00a0in mice","volume":"301","author":"Miyamoto","year":"2011","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.apsb.2022.07.010_bib144","doi-asserted-by":"crossref","first-page":"283","DOI":"10.4049\/jimmunol.167.1.283","article-title":"IL-1 induced chemokine production through the association of Syk with TNF receptor-associated factor-6 in nasal fibroblast lines","volume":"167","author":"Yamada","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.apsb.2022.07.010_bib145","doi-asserted-by":"crossref","first-page":"10883","DOI":"10.1074\/jbc.M309901200","article-title":"Lipopolysaccharide-induced c-Jun NH2-terminal kinase activation in human neutrophils: role of phosphatidylinositol 3-kinase and Syk-mediated pathways","volume":"279","author":"Arndt","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2022.07.010_bib146","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/thx.2010.154005","article-title":"A direct role for vitamin D-binding protein in the pathogenesis of COPD?","volume":"66","author":"Dimeloe","year":"2011","journal-title":"Thorax"},{"key":"10.1016\/j.apsb.2022.07.010_bib147","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.tcb.2006.12.001","article-title":"HMG chromosomal proteins in development and disease","volume":"17","author":"Hock","year":"2007","journal-title":"Trends Cell Biol"},{"key":"10.1016\/j.apsb.2022.07.010_bib148","doi-asserted-by":"crossref","first-page":"484","DOI":"10.3389\/fimmu.2020.00484","article-title":"Targeting inflammation driven by HMGB1","volume":"11","author":"Yang","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2022.07.010_bib149","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1089\/nat.2012.0350","article-title":"Uniqueness, advantages, challenges, solutions, and perspectives in therapeutics applying RNA nanotechnology","volume":"22","author":"Guo","year":"2012","journal-title":"Nucleic Acid Therapeut"},{"key":"10.1016\/j.apsb.2022.07.010_bib150","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1097-2765(01)00212-X","article-title":"Interleukin 2 receptors and detergent-resistant membrane domains define a clathrin-independent endocytic pathway","volume":"7","author":"Lamaze","year":"2001","journal-title":"Mol Cell"},{"key":"10.1016\/j.apsb.2022.07.010_bib151","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jconrel.2016.03.029","article-title":"Targeted delivery of siRNA to activated T cells via transferrin-polyethylenimine (Tf-PEI) as a potential therapy of asthma","volume":"229","author":"Xie","year":"2016","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2022.07.010_bib152","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jconrel.2018.02.017","article-title":"In\u00a0vitro and in\u00a0vivo delivery of siRNA via VIPER polymer system to lung cells","volume":"276","author":"Feldmann","year":"2018","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2022.07.010_bib153","article-title":"Coming in and finding out: blending receptor-targeted delivery and efficient endosomal escape in a novel bio-responsive siRNA delivery system for gene knockdown in pulmonary T cells","volume":"2","author":"Kandil","year":"2019","journal-title":"Adv Ther"},{"key":"10.1016\/j.apsb.2022.07.010_bib154","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jconrel.2012.06.005","article-title":"An inhalable \u03b2\u2082-adrenoceptor ligand-directed guanidinylated chitosan carrier for targeted delivery of siRNA to lung","volume":"162","author":"Luo","year":"2012","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2022.07.010_bib155","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12931-014-0132-z","article-title":"Small interfering RNA against CD86 during allergen challenge blocks experimental allergic asthma","volume":"15","author":"Asai-Tajiri","year":"2014","journal-title":"Respir Res"},{"key":"10.1016\/j.apsb.2022.07.010_bib156","first-page":"5505","article-title":"Intranasal sirna targeting c-kit reduces airway inflammation in experimental allergic asthma","volume":"7","author":"Wu","year":"2014","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1016\/j.apsb.2022.07.010_bib157","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.omtn.2017.06.005","article-title":"Therapeutic miRNA and siRNA: moving from bench to clinic as next generation medicine","volume":"8","author":"Chakraborty","year":"2017","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.apsb.2022.07.010_bib158","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41392-019-0068-3","article-title":"Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles","volume":"4","author":"Singh","year":"2019","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.apsb.2022.07.010_bib159","first-page":"27","article-title":"Oxidative stress in chronic obstructive pulmonary disease: a lung and systemic process","volume":"20","author":"Eeden","year":"2013","journal-title":"Can Respir J"},{"key":"10.1016\/j.apsb.2022.07.010_bib160","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1034\/j.1399-3003.1999.13d24.x","article-title":"The cellular composition of induced sputum in chronic obstructive pulmonary disease","volume":"13","author":"Peleman","year":"1999","journal-title":"Eur Respir J"},{"key":"10.1016\/j.apsb.2022.07.010_bib161","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1164\/rccm.201405-0992OC","article-title":"CXCR2 antagonist MK-7123. a phase 2 proof-of-concept trial for chronic obstructive pulmonary disease","volume":"191","author":"Rennard","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.apsb.2022.07.010_bib162","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2174\/187152810792231904","article-title":"The role of nuclear factor-kappaB in inflammatory lung disease","volume":"9","author":"Imanifooladi","year":"2010","journal-title":"Inflamm Allergy Drug Targets"},{"key":"10.1016\/j.apsb.2022.07.010_bib163","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1124\/jpet.110.168518","article-title":"Phosphoinositide 3-kinase gamma regulates airway smooth muscle contraction by modulating calcium oscillations","volume":"334","author":"Jiang","year":"2010","journal-title":"J Pharmacol Exp Therapeut"},{"key":"10.1016\/j.apsb.2022.07.010_bib164","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1042\/CS20130182","article-title":"Recent advances in pre-clinical mouse models of COPD","volume":"126","author":"Vlahos","year":"2014","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.apsb.2022.07.010_bib165","unstructured":"Topigen Pharmaceuticals Inc. Moves novel inhaled PDE inhibitor, TPI 1100, into clinical development for COPD. Available from: https:\/\/www.biospace.com\/article\/topigen-pharmaceuticals-inc-moves-novel-inhaled-pde-inhibitor-tpi-1100-into-clinical-development-for-copd-\/. [accessed February 1, 2022]."},{"key":"10.1016\/j.apsb.2022.07.010_bib166","author":"Pharmaxis"},{"key":"10.1016\/j.apsb.2022.07.010_bib167","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201700478","article-title":"Aspherical, nanostructured microparticles for targeted gene delivery to alveolar macrophages","volume":"6","author":"M\u00f6hwald","year":"2017","journal-title":"Adv Healthc Mater"},{"key":"10.1016\/j.apsb.2022.07.010_bib168","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/AIA.0000000000000177","article-title":"The basic science and molecular mechanisms of lung injury and acute respiratory distress syndrome","volume":"56","author":"Aranda-Valderrama","year":"2018","journal-title":"Int Anesthesiol Clin"},{"key":"10.1016\/j.apsb.2022.07.010_bib169","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1146\/annurev-pathol-011110-130158","article-title":"The acute respiratory distress syndrome: pathogenesis and treatment","volume":"6","author":"Matthay","year":"2011","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.apsb.2022.07.010_bib170","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/thx.53.10.815","article-title":"The acute respiratory distress syndrome: fibrosis in the fast lane","volume":"53","author":"Marshall","year":"1998","journal-title":"Thorax"},{"key":"10.1016\/j.apsb.2022.07.010_bib171","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1007\/s00134-020-06299-6","article-title":"Current and evolving standards of care for patients with ARDS","volume":"46","author":"Menk","year":"2020","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.apsb.2022.07.010_bib172","doi-asserted-by":"crossref","first-page":"10677","DOI":"10.1074\/jbc.M312941200","article-title":"Small interfering RNA targeting heme oxygenase-1 enhances ischemia-reperfusion-induced lung apoptosis","volume":"279","author":"Zhang","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2022.07.010_bib173","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/SHK.0b013e318254fa6a","article-title":"The role and source of TNF-\u03b1 in hemorrhage-induced priming for septic lung injury","volume":"37","author":"Lomas-Neira","year":"2012","journal-title":"Shock"},{"key":"10.1016\/j.apsb.2022.07.010_bib174","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.pharmthera.2007.05.011","article-title":"Sphingosine-1-phosphate in allergic responses, asthma and anaphylaxis","volume":"115","author":"Oskeritzian","year":"2007","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.apsb.2022.07.010_bib175","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/nri1594","article-title":"High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal","volume":"5","author":"Lotze","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.apsb.2022.07.010_bib176","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1080\/14728222.2018.1464139","article-title":"MyD88 as a therapeutic target for inflammatory lung diseases","volume":"22","author":"Di Padova","year":"2018","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.apsb.2022.07.010_bib177","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jss.2013.11.1107","article-title":"Resolvin D1 attenuates lipopolysaccharide induced acute lung injury through CXCL-12\/CXCR4 pathway","volume":"188","author":"Wang","year":"2014","journal-title":"J Surg Res"},{"key":"10.1016\/j.apsb.2022.07.010_bib178","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00134-009-1690-2","article-title":"Elevated PAI-1 is associated with poor clinical outcomes in pediatric patients with acute lung injury","volume":"36","author":"Sapru","year":"2010","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.apsb.2022.07.010_bib179","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.trsl.2019.07.006","article-title":"Efficient nanocarriers of siRNA therapeutics for cancer treatment","volume":"214","author":"Subhan","year":"2019","journal-title":"Transl Res"},{"key":"10.1016\/j.apsb.2022.07.010_bib181","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.3390\/pharmaceutics13071009","article-title":"Clinical advances of siRNA-based nanotherapeutics for cancer treatment","volume":"13","author":"Hattab","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.apsb.2022.07.010_bib182","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1016\/j.biomaterials.2013.01.077","article-title":"Hyaluronic acid based self-assembling nanosystems for CD44 target mediated siRNA delivery to solid tumors","volume":"34","author":"Ganesh","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2022.07.010_bib183","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1038\/mt.2014.18","article-title":"Synthetic lethal therapy for KRAS mutant non-small-cell lung carcinoma with nanoparticle-mediated CDK4 siRNA delivery","volume":"22","author":"Mao","year":"2014","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2022.07.010_bib184","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s11095-019-2665-9","article-title":"Targeting KRAS mutant lung cancer cells with siRNA-loaded bovine serum albumin nanoparticles","volume":"36","author":"Mehta","year":"2019","journal-title":"Pharm Res (N Y)"},{"key":"10.1016\/j.apsb.2022.07.010_bib185","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/emmm.201100176","article-title":"Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils","volume":"3","author":"Torti","year":"2011","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.apsb.2022.07.010_bib186","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/jcp.27021","article-title":"Combination therapy with KRAS siRNA and EGFR inhibitor AZD8931 suppresses lung cancer cell growth in\u00a0vitro","volume":"234","author":"Zarredar","year":"2019","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.apsb.2022.07.010_bib187","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1080\/10717544.2019.1606363","article-title":"Codelivery of DOX and siRNA by folate-biotin-quaternized starch nanoparticles for promoting synergistic suppression of human lung cancer cells","volume":"26","author":"Li","year":"2019","journal-title":"Drug Deliv"},{"key":"10.1016\/j.apsb.2022.07.010_bib188","doi-asserted-by":"crossref","first-page":"11414","DOI":"10.1039\/D1NR02179F","article-title":"Multi-component bioresponsive nanoparticles for synchronous delivery of docetaxel and TUBB3 siRNA to lung cancer cells","volume":"13","author":"Conte","year":"2021","journal-title":"Nanoscale"},{"key":"10.1016\/j.apsb.2022.07.010_bib189","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1073\/pnas.84.14.5034","article-title":"Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma","volume":"84","author":"Staal","year":"1987","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2022.07.010_bib190","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1016\/j.biomaterials.2008.02.018","article-title":"Poly(beta-amino ester) as a carrier for si\/shRNA delivery in lung cancer cells","volume":"29","author":"Jere","year":"2008","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2022.07.010_bib191","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1164\/rccm.200707-1022OC","article-title":"Poly(ester amine)-mediated, aerosol-delivered Akt1 small interfering RNA suppresses lung tumorigenesis","volume":"178","author":"Xu","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.apsb.2022.07.010_bib192","doi-asserted-by":"crossref","first-page":"5287","DOI":"10.2147\/IJN.S203113","article-title":"Antitumor effect of hyaluronic-acid-modified chitosan nanoparticles loaded with siRNA for targeted therapy for non-small cell lung cancer","volume":"14","author":"Zhang","year":"2019","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.apsb.2022.07.010_bib193","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1080\/10717544.2018.1440668","article-title":"Water-soluble substituted chitosan derivatives as technology platform for inhalation delivery of siRNA","volume":"25","author":"Capel","year":"2018","journal-title":"Drug Deliv"},{"key":"10.1016\/j.apsb.2022.07.010_bib194","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s11095-018-2460-z","article-title":"Bioreducible poly(amino ethers) based mTOR siRNA delivery for lung cancer","volume":"35","author":"Gandhi","year":"2018","journal-title":"Pharm Res (N Y)"},{"key":"10.1016\/j.apsb.2022.07.010_bib195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0077121","article-title":"Knockdown of the sodium-dependent phosphate co-transporter 2b (NPT2b) suppresses lung tumorigenesis","volume":"8","author":"Hong","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2022.07.010_bib196","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/j.ymthe.2019.08.008","article-title":"Increased survival by pulmonary treatment of established lung metastases with dual STAT3\/CXCR4 inhibition by siRNA nanoemulsions","volume":"27","author":"Li","year":"2019","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2022.07.010_bib197","doi-asserted-by":"crossref","DOI":"10.1002\/adtp.201900039","article-title":"Perfluorocarbon nanoemulsions for combined pulmonary siRNA treatment of lung metastatic osteosarcoma","volume":"2","author":"Li","year":"2019","journal-title":"Adv Therap"},{"key":"10.1016\/j.apsb.2022.07.010_bib198","article-title":"Folate receptor-targeted RNAi nanoparticles for silencing STAT3 in tumor-associated macrophages and tumor cells","volume":"25","author":"Chen","year":"2020","journal-title":"Nanomedicine"},{"key":"10.1016\/j.apsb.2022.07.010_bib199","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jin2.63","article-title":"Functional recovery of natural killer cell activity by nanoparticle-mediated delivery of transforming growth factor beta 2 small interfering RNA","volume":"4","author":"Adjei","year":"2019","journal-title":"J Interdiscip Nanomed"},{"key":"10.1016\/j.apsb.2022.07.010_bib200","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.1002\/adfm.201501283","article-title":"Dual targeted immunotherapy via in\u00a0vivo delivery of biohybrid RNAi-peptide nanoparticles to tumour-associated macrophages and cancer cells","volume":"25","author":"Conde","year":"2015","journal-title":"Adv Funct Mater"},{"key":"10.1016\/j.apsb.2022.07.010_bib201","doi-asserted-by":"crossref","first-page":"4321","DOI":"10.1002\/smll.201501034","article-title":"Pulmonary\u00a0codelivery of doxorubicin and siRNA by pH-sensitive nanoparticles for therapy of metastatic lung cancer","volume":"11","author":"Xu","year":"2015","journal-title":"Small"},{"key":"10.1016\/j.apsb.2022.07.010_bib202","doi-asserted-by":"crossref","first-page":"7744","DOI":"10.1016\/j.biomaterials.2013.06.041","article-title":"Vivo tumor targeting via nanoparticle-mediated therapeutic siRNA coupled to inflammatory response in lung cancer mouse models","volume":"34","author":"Conde","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2022.07.010_bib203","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/mt.2013.10","article-title":"Enhanced intrapulmonary delivery of anticancer siRNA for lung cancer therapy using cationic ethylphosphocholine-based nanolipoplexes","volume":"21","author":"Shim","year":"2013","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2022.07.010_bib204","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1039\/C6BM00601A","article-title":"The suppression of metastatic lung cancer by pulmonary administration of polymer nanoparticles for co-delivery of doxorubicin and Survivin siRNA","volume":"4","author":"Xu","year":"2016","journal-title":"Biomater Sci"},{"key":"10.1016\/j.apsb.2022.07.010_bib205","first-page":"9","article-title":"Implications of insulin-like growth factor 1 receptor activation in lung cancer","volume":"23","author":"Nurwidya","year":"2016","journal-title":"Malays J Med Sci"},{"key":"10.1016\/j.apsb.2022.07.010_bib206","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1210\/en.2012-1348","article-title":"Diverse functions of IGF\/insulin signaling in malignant and\u00a0noncancerous prostate cells: proliferation in cancer cells and differentiation in noncancerous cells","volume":"153","author":"Heidegger","year":"2012","journal-title":"Endocrinology"},{"key":"10.1016\/j.apsb.2022.07.010_bib207","doi-asserted-by":"crossref","first-page":"16807","DOI":"10.18632\/oncotarget.24704","article-title":"Novel drug-resistance mechanisms of pemetrexed-treated non-small cell lung cancer","volume":"9","author":"Tanino","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.apsb.2022.07.010_bib208","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ijpharm.2017.06.071","article-title":"Co-delivery of paclitaxel and anti-survivin siRNA via redox-sensitive oligopeptide liposomes for the synergistic treatment of breast cancer and metastasis","volume":"529","author":"Chen","year":"2017","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2022.07.010_bib209","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.3892\/ol.2015.3374","article-title":"Survivin expression in lung cancer: association with smoking, histological types and pathological stages","volume":"10","author":"Hirano","year":"2015","journal-title":"Oncol Lett"},{"key":"10.1016\/j.apsb.2022.07.010_bib210","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1158\/0008-5472.CAN-14-2740","article-title":"TUBB3\/\u03b2III-tubulin acts through the PTEN\/AKT signaling axis to promote tumorigenesis and anoikis resistance in non-small cell lung cancer","volume":"75","author":"McCarroll","year":"2015","journal-title":"Cancer Res"},{"issue":"Suppl","key":"10.1016\/j.apsb.2022.07.010_bib211","article-title":"Sustained proliferation in cancer: mechanisms and novel therapeutic targets","volume":"35","author":"Feitelson","year":"2015","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.apsb.2022.07.010_bib212","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ijpharm.2009.05.046","article-title":"Chitosan-graft-polyethylenimine for Akt1 siRNA delivery to lung cancer cells","volume":"378","author":"Jere","year":"2009","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2022.07.010_bib213","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/s41467-017-00450-6","article-title":"Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer","volume":"8","author":"Jacobsen","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2022.07.010_bib214","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/1759-7714.13328","article-title":"Targeting the PI3K\/Akt\/mTOR pathway in non-small cell lung cancer (NSCLC)","volume":"11","author":"Tan","year":"2020","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.apsb.2022.07.010_bib215","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature07205","article-title":"Cancer-related inflammation","volume":"454","author":"Mantovani","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2022.07.010_bib216","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41423-019-0306-1","article-title":"Myeloid immunosuppression and immune checkpoints in the tumor microenvironment","volume":"17","author":"Nakamura","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.apsb.2022.07.010_bib217","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jconrel.2021.02.002","article-title":"Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy","volume":"332","author":"Kim","year":"2021","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2022.07.010_bib218","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1007\/s00262-019-02384-y","article-title":"Tumor-induced peripheral immunosuppression promotes brain metastasis in patients with non-small cell lung cancer","volume":"68","author":"Li","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.apsb.2022.07.010_bib219","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","article-title":"Delivery technologies for cancer immunotherapy","volume":"18","author":"Riley","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2022.07.010_bib220","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nrc2734","article-title":"STATs in cancer inflammation and immunity: a leading role for STAT3","volume":"9","author":"Yu","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.apsb.2022.07.010_bib221","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.omtn.2018.03.006","article-title":"Gelofusine attenuates tubulointerstitial injury induced by cRGD-conjugated siRNA by regulating the TLR3 signaling pathway","volume":"11","author":"Cen","year":"2018","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.apsb.2022.07.010_bib222","doi-asserted-by":"crossref","first-page":"5554","DOI":"10.1158\/0008-5472.CAN-04-4570","article-title":"Bcl-2 promotes invasion and lung metastasis by inducing matrix metalloproteinase-2","volume":"65","author":"Choi","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2022.07.010_bib223","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/jcmm.12159","article-title":"Gene polymorphisms and chronic obstructive pulmonary disease","volume":"18","author":"Wu","year":"2014","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.apsb.2022.07.010_bib224","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nrc2734","article-title":"STATs in cancer inflammation and immunity: a leading role for STAT3","volume":"9","author":"Yu","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.apsb.2022.07.010_bib225","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1038\/sj.onc.1203551","article-title":"Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors","volume":"19","author":"Hirano","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.apsb.2022.07.010_bib226","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1261\/rna.28106","article-title":"Off-target effects by siRNA can induce toxic phenotype","volume":"12","author":"Fedorov","year":"2006","journal-title":"RNA"},{"key":"10.1016\/j.apsb.2022.07.010_bib227","doi-asserted-by":"crossref","first-page":"971","DOI":"10.3389\/fphar.2018.00971","article-title":"Non-viral delivery of nucleic acids: insight into mechanisms of overcoming intracellular barriers","volume":"9","author":"Durymanov","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.apsb.2022.07.010_bib228","doi-asserted-by":"crossref","first-page":"232","DOI":"10.4067\/S0717-95022016000100033","article-title":"Tracheal length in adult human: the results of 100 autopsies","volume":"34","author":"Cinar","year":"2016","journal-title":"Int J Morphol"},{"key":"10.1016\/j.apsb.2022.07.010_bib229","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1177\/0023677218765032","article-title":"Optimal tube\u00a0length of orotracheal intubation for mice","volume":"53","author":"Nosaka","year":"2019","journal-title":"Lab Anim"},{"key":"10.1016\/j.apsb.2022.07.010_bib230","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3389\/fgene.2019.00170","article-title":"FGF signaling in lung development and disease: human versus mouse","volume":"10","author":"Danopoulos","year":"2019","journal-title":"Front Genet"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383522003227?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383522003227?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T17:02:47Z","timestamp":1761930167000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383522003227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":226,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S2211383522003227"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2022.07.010","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progress in non-viral localized delivery of siRNA therapeutics for pulmonary diseases","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2022.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}